secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001193125-24-086214
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks removes CFO Christopher Astle effective March 31; severance $425,000
------------------------------------------------------------------------------

- Astle removed as CFO and principal accounting officer without cause, effective March 31, 2024.
- Severance package includes $425,000 lump sum (12 months' base salary) and 12 months of health benefits.
- Astle retains 92,369 vested stock options (90 days to exercise); 146,881 unvested options and 51,000 unvested RSUs forfeited.
- CEO Kenneth Galbraith serves as interim CFO; no permanent replacement announced.
- Separation agreement includes non-solicitation, non-competition, and confidentiality covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524086214/0001193125-24-086214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524086214/d821869d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-086214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer